Use of drugs to improve athletic performance;Gebruik van geneesmiddelen voor het verbeteren van sportprestaties

Nederlands Tijdschrift voor Geneeskunde

Volumn 141, Issue 41, 1997, Pages 1965-1968

  Kuipers, H ^a,b   Hartgens, F ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b Nederlands Ctr V D   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; ERYTHROPOIETIN; GROWTH HORMONE; STEROID;

ATHLETE; DRUG ABUSE; DRUG SAFETY; DRUG USE; HUMAN; REVIEW; SPORTS MEDICINE;

ADRENERGIC BETA-AGONISTS; AMPHETAMINES; ANABOLIC AGENTS; ANDROGENS; CAFFEINE; CENTRAL NERVOUS SYSTEM STIMULANTS; DOPING IN SPORTS; FEMALE; HUMAN GROWTH HORMONE; HUMANS; MALE;

EID: 0030762978     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (33)

1. Stoele FWJ. Doping, cijfers en trivia. Handleiding dopingcontrole. Arnhem: Nederlands Centrum voor Dopingvraagstukken, 1995.
2. Delbeke FT. Doping in cyclism: results of unannounced controls in Flandres (1987-1994). Int J Sports Med 1996;17:434-8.
3. Schwenk T. Psychoactive drugs and athletic performance. Phys Sportsmed 1997;25:32-46.
4. Ivy JL. Amphetamines. In: Williams MH, editor. Ergogenic aids in sport. Champaign, Ill.: Human Kinetics, 1983.101-27.
5. Conlee RK. Amphetamines, caffeine, and cocaine. In: Lamb DR, Williams MH. editors. Perspectives in exercise science and sports medicine. Vol 4. Ergogenics. Ann Arbor: Brown & Benchmark, 1991:285-330
6. Laties VG, Weiss B. The amphetamine margin in sports. Fed Proc 1981;40:2689-92.
7. Droogenbroeck P, Deboeck M, Hueting J, Soetens E, Amfetamine verhoogt de minimale prestatie. Geneeskunde en sport 1983;16:2-10.
8. International Olympic Committee (IOC). List of prohibited classes of substances and prohibited methods. Lausanne: IOC, 1996.
9. Pasman WJ, Baak MA van, Jeukendrup AE, Haan A de. The effect of different dosages of caffeine on endurance performance time Int J Sports Med 1995;16:225-30.
10. Hartgens F. Misbruik van androgene-anabole steroïden in de sport. Patient Care 1997;24:14-24.
11. Kleij R van. Doping voor de vorm, een gezondheidsprobleem? Rotterdam: Nederlands Centrum voor Dopingvraagstukken, 1996.
12. Yesalis CE. Anabolic steroids in sport and exercise. Champaign, Ill.: Human Kinetics. 1993.
13. Griggs RC, Kingston W, Jozefowicz RF, Herr BE, Forbes G, Halliday D. Effect of testosterone on muscle mass and muscle protein synthesis. J Appl Physiol 1989;66:498-503.
14. American College of Sports Medicine. Position stand of American College of Sports Medicine on the use of anabolic-androgenic steroids in sport. Med Sci Sports Exerc 1987;19:534-9.
15. Hartgens F. Doping anno 1996. Geneesmiddelenbulletin 1996;30: 125-32.
16. Boer A de, Haren SF van, Hartgens F, Boer D de, Porsius AJ. Onderzoek naar het gebruik van prestatieverhogende middelen bij bodybuilders in Nederland. Rotterdam/Utrecht: Nederlands Centrum voor Dopingvraagstukken/Universiteit Utrecht, 1996.
17. Rockhold RW. Cardiovascular toxicity of anabolic steroids. Annu Rev Pharmacol Toxicol 1993;33:497-520.
18. De Piccoli B, Giada F, Benettin A, Sartori F, Piccolo E. Anabolic steroid use in body builders. Int J Sports Med 1991;12:408-12.
19. Urhausen A, Hölpes R, Kinderman W. One- and two-dimensional echocardiography in bodybuilders using anabolic steroids. Eur J Appl Physiol 1989;58:633-40.
20. Cheriex E, Hartgens F, Gordijn T, Depuydt K, Keizer HA, Kuipers H. Cardiac dimensions and function are not affected by eight weeks androgenic-anabolic steroids use [abstract], Med Sci Sports Exerc 1996;28:S35.
21. Bahrke MS, Yesalis 3rd CE, Wright JE. Psychological and behavioural effects of endogenous testosterone and anabolic-androgenic steroids. An update. Sports Med 1996;22:367-90.
22. Prather ID, Brown DE, North P, Wilson JR. Clenbuterol: a substitute for anabolic steroids? Med Sci Sports Exerc 1995;27:1118-21.
23. Dodd SL, Powers SK, Vrabas IS, Criswell D, Stetson S, Hussain R. Effects of clenbuterol on contractile and biochemical properties of skeletal muscle. Med Sci Sports Exerc 1996;28:669-76.
24. Caruso JF, Signorile JF, Perry AC, Leblanc B, Williams R, Clark M, et al. The effects of albuterol and isokinetic exercise on the quadriceps muscle group Med Sci Sports Exerc 1995;27:1471-6.
25. Signorile JF, Kaplan TA, Applegate B, Perry AC. Effects of acute inhalation of the bronchodilator, albuterol, on power output. Med Sci Sports Exerc 1992;24:638-42.
26. Yarasheski KE. Growth hormone effects on metabolism, muscle mass, and strength In: Holloszy HO, editor. Exercise and sport sciences reviews. Vol 22. Londen: Williams & Wilkins, 1994;285-312.
27. Spriet LL. Blood doping and oxygen transport. In: Lamb DR, Williams MH, editors. Perspectives in exercise science and sports medicine Vol 4. Ergogenics. Ann Arbor: Brown & Benchmark, 1991:213-48.
28. American College of Sports Medicine. Position stand of American College of Sports Medicine on the use of blood doping as an ergogenic aid Med Sci Sports Exerc 1996;28:I-VII.
29. Ekblom B, Berglund B. Effect of erythropoietin administration on maximal aerobic power. Scand J Med Sci Sports 1991;1:88-93.
30. Brien AJ, Simon TL. The effects of red blood cell infusion on 10-km race time. JAMA 1987;257:2761-5.
31. Dunn CJ, Markham A. Epoetin beta. A review of its pharmacological properties and clinical use in the management of anaemia associated with chronic renal failure. Drugs 1996;51:299-318.
32. Koninklijke Nederlandsche Maatschappij tot bevordering der Geneeskunst (KNMG) Gedragsregels voor arisen. Utrecht: KNMG, 1996.
33. Vereniging voor Sportgeneeskunde (VSG). Richtlijnen voor artsen omtrent het sportmedisch handelen. Utrecht: VSG, 1996.